Lundbeck's Rexulti Growth Hopes Clouded By Dementia Agitation Data Setback

Denmark-based Lundbeck's plans to make Rexulti the first approved drug for agitation associated with dementia have been knocked back by mixed clinical data, necessitating another Phase III trial.

MRI
Rexulti Needs Deciding Phase III Trial In Dementia-Related Agitation • Source: Shutterstock

Ambiguous data from two Phase III trials treating agitation in patients with dementia of the Alzheimer's type using Rexulti (brexpiprazole) were deemed insufficient by FDA, prompting plans by H. Lundbeck A/S and its Japanese partner to initiate a third study around the second quarter of this year, according to the brain-focused Danish biotech.

"We will initiate a third study together with Otsuka Pharmaceutical Co. Ltd. and expect to do that sometime during...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category